We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+32.61%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$439M
AUM Growth
+$21.9M
Cap. Flow
-$50M
Cap. Flow %
-11.37%
Top 10 Hldgs %
49.48%
Holding
86
New
10
Increased
12
Reduced
30
Closed
14

Top Buys

Rank Stock Value
1
ATRC icon
AtriCure
ATRC
+$4.87M
2
PODD icon
Insulet
PODD
+$2.97M
3
KALV
KalVista Pharmaceuticals
KALV
+$2.75M
4
CATX icon
Perspective Therapeutics
CATX
+$2.65M
5
LRMR icon
Larimar Therapeutics
LRMR
+$2.59M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$15.2M
2
IMGN
Immunogen Inc
IMGN
+$5.74M
3
SAGE
Sage Therapeutics
SAGE
+$5.31M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$5.25M
5
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$4.9M

Sector Composition

Rank Sector Weight
1 Healthcare 86.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IPSC icon
26
Century Therapeutics
IPSC
$343M
$5.46M 1.24%
1,307,407
– –
LRMR icon
27
Larimar Therapeutics
LRMR
$436M
$4.98M 1.13%
656,373
+332,500
+103% +$2.59M
KROS icon
28
Keros Therapeutics
KROS
$211M
$4.49M 1.02%
67,754
-6,607
-9% -$392K
RCUS icon
29
Arcus Biosciences
RCUS
$3.56B
$4.37M 1%
231,717
-1,000
-0.4% -$17.3K
LKFT
30
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
$4.19M 0.95%
130,175
– –
CATX icon
31
Perspective Therapeutics
CATX
$339M
$3.69M 0.84%
+310,364
New +$2.65M
BCRX icon
32
BioCryst Pharmaceuticals
BCRX
$2.36B
$3.6M 0.82%
709,500
– –
ATXS
33
DELISTED
Astria Therapeutics
ATXS
$3.14M 0.72%
223,265
-225,743
-50% -$2.81M
RGLS
34
DELISTED
Regulus Therapeutics
RGLS
$3.08M 0.7%
1,070,548
-40,501
-4% -$66K
BCYC
35
Bicycle Therapeutics
BCYC
$278M
$3.04M 0.69%
122,200
– –
ARAY icon
36
Accuray
ARAY
$33.8M
$3.02M 0.69%
1,222,358
– –
PODD icon
37
Insulet
PODD
$9.65B
$2.73M 0.62%
+15,900
New +$2.97M
PRCT icon
38
Procept Biorobotics
PRCT
$1.14B
$2.72M 0.62%
54,995
-8,305
-13% -$395K
MDWD icon
39
MediWound
MDWD
$184M
$2.69M 0.61%
188,753
-68,900
-27% -$944K
SPRY icon
40
ARS Pharmaceuticals
SPRY
$551M
$2.44M 0.56%
239,194
-71,975
-23% -$537K
AQST icon
41
Aquestive Therapeutics
AQST
$492M
$2.13M 0.48%
+500,000
New +$1.66M
PRQR icon
42
ProQR Therapeutics
PRQR
$268M
$2.07M 0.47%
905,582
-35,000
-4% -$74.8K
CMPS
43
Compass Pathways
CMPS
$1.83B
$2.02M 0.46%
243,210
+50,210
+26% +$506K
LCTX icon
44
Lineage Cell Therapeutics
LCTX
$282M
$2.02M 0.46%
+1,366,308
New +$1.55M
STOK icon
45
Stoke Therapeutics
STOK
$2.06B
$1.96M 0.45%
+145,000
New +$878K
STRO icon
46
Sutro Biopharma
STRO
$400M
$1.89M 0.43%
33,408
+5,100
+18% +$225K
INGN icon
47
Inogen
INGN
$176M
$1.68M 0.38%
208,790
+193,790
+1,292% +$1.37M
GOSS icon
48
Gossamer Bio
GOSS
$87.2M
$1.66M 0.38%
1,409,262
-66,790
-5% -$73.5K
BWAY
49
Brainsway
BWAY
$628M
$1.57M 0.36%
595,310
-21,632
-4% -$67.5K
BNTX icon
50
BioNTech
BNTX
$22.9B
$1.57M 0.36%
+17,000
New +$1.63M
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, DAFNA Capital Management held 86 positions worth $439M, up 5.3% from $417M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

DAFNA Capital Management withdrew a net $50M in Q1 2024, closing 14 positions and reducing 30 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $15.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Insulet worth $2.73M.

  • DAFNA Capital Management's largest Q1 2024 buy was Insulet: 15,900 shares worth $2.73M.
  • DAFNA Capital Management added most to AtriCure in Q1 2024, an estimated $4.87M increase.
  • DAFNA Capital Management's biggest Q1 2024 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $4.9M.
  • DAFNA Capital Management fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $15.2M.
  • DAFNA Capital Management's ten largest holdings make up 49% of its $439M portfolio in Q1 2024.
  • DAFNA Capital Management opened 10 new positions and closed 14 in Q1 2024.
  • DAFNA Capital Management's portfolio value rose 5.3% quarter-over-quarter to $439M.

Based on DAFNA Capital Management's 13F filing for Q1 2024, filed 15 May 2024.